Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Synlogic Inc
SYBXCurrent price
1.46 USD
-0.065 USD (-4.26%)
Last closed
1.44 USD
Company
www.synlogictx.com
ISIN
US87166L1008
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
16 608 461 USD
Yield for 12 month
-21.51 %
1Y
3Y
5Y
10Y
15Y
SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. Address: 301 Binney Street, Cambridge, MA, United States, 02142
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 USDP/E ratio
–Dividend Yield
–Current Year
+3 371 000 USD
Last Year
+1 180 000 USD
Current Quarter
–
Last Quarter
+8 000 USD
Current Year
-1 924 000 USD
Last Year
-4 489 000 USD
Current Quarter
–
Last Quarter
-1 287 000 USD
Key Figures SYBX
1 year
3 years
5 years
10 years
EBITDA
-35 997 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-46.07 %
PEG Ratio
–
Return On Equity TTM
-158.75 %
Wall Street Target Price
1 USD
Revenue TTM
3 170 000 USD
Book Value
1.37 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-95.4 %
Dividend Yield
–
Gross Profit TTM
1 180 000 USD
Earnings per share
-4.63 USD
Diluted Eps TTM
-4.63 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SYBX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SYBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:7
Payout Ratio
–
Last Split Date
28.08.2017
Dividend Date
28.08.2017
Stock Valuation SYBX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.3489
Price Sales TTM
5.2393
Enterprise Value EBITDA
0.1803
Price Book MRQ
1.0391
Financials SYBX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SYBX
For 52 weeks
1.22 USD
5.12 USD
50 Day MA
1.47 USD
Shares Short Prior Month
55 279
200 Day MA
1.81 USD
Short Ratio
4.91
Shares Short
53 418
Short Percent
1.31 %
BeatStart